Treating generalized anxiety disorder with second generation antipsychotics: A systematic review and meta-analysis

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 326-333

  Lalonde, Carlos D ^a   Van Lieshout, Ryan J ^b  

^a Homewood Health Centre Guelph   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

antipsychotic agents; atypical antipsychotics; generalized anxiety disorder; meta analysis; second generation antipsychotics

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; ESCITALOPRAM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MEDLINE; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955616739     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31821b2b3f     Document Type: Article

References (48)

1. Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
2. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand. 1998;393(suppl):6-11. (Pubitemid 28428186)
3. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry. 2009;70(suppl 2):20-24.
4. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162-171.
5. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry. 1993;150:600-607. (Pubitemid 23109929)
6. Canadian Psychiatric Association. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry. 2006;51:1S-93S.
7. Rubio G, Lopez-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand. 2007;115:372-379. (Pubitemid 46570059)
8. Yonkers KA, Warshaw MG, Massion AO, et al. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry. 1996;168:308-313.
9. Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009;70:32-38.
10. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47:170-174. (Pubitemid 16109750)
11. Romain JL, Dermain P, Gresle P, et al. Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study. Encephale. 1996;22:280-286. (Pubitemid 26364061)
12. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;4:CD005473.
13. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491. (Pubitemid 44166336)
14. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31:150-153. (Pubitemid 34284917)
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available at: http://www.cochrane-handbook.org. Accessed October 25, 2009.
17. GRADE Working Group. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328:1-8.
18. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
20. Cates CJ. Visual Rx [Web-based Calculator]. Available at: http://www.nntonline.net; 2008. Accessed November 30, 2009.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. (Pubitemid 34746062)
22. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. Br Med J. 2003;326:219. (Pubitemid 36143396)
23. Moher D, Liberati A, Tetzlaff J, et al, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
24. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992.
25. Katzman MA, Vermani M, Jacobs L, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22:1480-1486.
26. Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67:381-385.
27. Hoge EA, Worthington JJ III, Kaufman BA, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13:522-527. (Pubitemid 351960777)
28. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27:207-210. (Pubitemid 46594942)
29. Kinrys G, Nery F, Coleman E, et al. Aripiprazole augmentation for treatment refractory GAD. Presented at: American Psychiatric Association Annual Meeting; 2006.
30. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25:497-498.
31. Cohen J. A power primer. Psychol Bull. 1992;112:155-159.
32. Thomas HM. A double-blind, randomized, prospective study to evaluate adjunctive risperidone versus adjunctive placebo in generalized anxiety disorder sub-optimally responsive to standard psychotropic therapy. 2005. Available at: http://download.veritasmedicine.com/PDF/ CR004696-CSR.pdf. Accessed November 3, 2009. No. CR004696.
33. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211-215. (Pubitemid 43208966)
34. Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharm Bull. 2007;40: 41-57.
35. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321-1325. (Pubitemid 41546513)
36. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008;197: 675-681.
37. A multicenter, randomized, double-blind, parallel-group, placebo controlled study of the efficacy and safety of quetiapine fumarate extended-release (quetiapine XR) compared with placebo as an adjunct to treatment in patients with GAD who demonstrate partial or no response to SSRI or SNRI alone or in combination with benzodiazepines. Palladium study. 2009. Available at: www.astrazenecaclinicaltrials.com/clinicaltrials/seroquel. Accessed November 3, 2009.
38. Klieser E, Wurthmann C, Czekalla J, et al. Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low dosages of the atypical antipsychotic. Eur Neuropsychopharmacol. 2000;10(suppl 3):S344.
39. Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry. 2005;66:544. (Pubitemid 40593589)
40. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305-320.
41. Meredith C, Cutler A, Neijber A. Efficacy and tolerability of extended-release quetiapine fumarate monotherapy in the treatment of GADVGold study. Eur Neuropsychopharmacol. 2008;18:S499-S500.
42. Brawman-Mintzer O. Quetiapine monotherapy in patients with GAD. Presented at the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
43. Joyce M, Khan A, Atkinson S. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with GADVTitanium study. Presented at 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC. No. D1448C00009.
44. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864-872. (Pubitemid 350029180)
45. Pollack MH, OttoMW, Roy-Byrne PP, et al. Novel treatment approached for refractory anxiety disorders. Depress Anxiety. 2008;25:467-476. (Pubitemid 351898386)
46. National Institute for Health and Clinical Excellence. Clinical Guideline 22 (Amended). Anxiety: Management of Anxiety (Panic Disorder, With or Without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. [NICE Web Site]. 2007. Available at: http://www.nice.org.uk/ CG022NICEguideline. Accessed December 20, 2009.
47. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567-596. (Pubitemid 41578819)
48. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disordersVfirst revision. World J Biol Psychiatry. 2008;9:248-312.